Inter-reader agreement of the PI-QUAL score for prostate MRI quality in the NeuroSAFE PROOF trial.
Francesco GigantiEoin DinneenVeeru KasivisvanathanAiman HaiderAlex FreemanAlex KirkhamShonit PunwaniMark EmbertonGreg ShawCaroline M MooreClare AllenPublished in: European radiology (2021)
• Inter-reader agreement for each single Prostate Imaging Quality (PI-QUAL) score (i.e., PI-QUAL 1 to PI-QUAL 5) was strong, with weighted kappa = 0.85 (95% confidence intervals: 0.51 - 1) and percent agreement = 84%. • Interobserver agreement was strong when the scans were clustered into three groups according to the ability (or not) to rule in and to rule out clinically significant prostate cancer (i.e., PI-QUAL 1-2 vs PI-QUAL 3 vs PI-QUAL 4-5), with weighted kappa = 0.82 (95% confidence intervals: 0.68 - 0.96) and percent agreement = 84%. • T2-weighted acquisitions were the most compliant with the Prostate Imaging Reporting and Data System (PI-RADS) v. 2.0 technical recommendations and were the sequences of highest diagnostic quality for both readers in 95/103 (92%) scans, followed by dynamic contrast enhanced acquisition with 81/103 (79%) scans and lastly by diffusion-weighted imaging with 79/103 (77%) scans.
Keyphrases
- prostate cancer
- contrast enhanced
- computed tomography
- diffusion weighted imaging
- magnetic resonance imaging
- magnetic resonance
- high resolution
- radical prostatectomy
- clinical trial
- nuclear factor
- emergency department
- photodynamic therapy
- machine learning
- dual energy
- inflammatory response
- toll like receptor
- phase ii
- adverse drug
- placebo controlled